Semaglutide 2.4 mg Weekly vs. Liraglutide 3.0 mg Daily Weight Management Trial Completes Phase 3
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
Study Design
Population
Overweight or obese adults were studied in this Phase 3 trial (NCT04074161).
Intervention
Semaglutide 2.4 mg was administered weekly for 68 weeks.
Comparator
Liraglutide 3.0 mg was administered daily.
Outcome
The primary endpoint was weight management.
Abstract
A completed Phase 3 trial (NCT04074161) compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily for weight management in overweight/obese adults over 68 weeks.